OTC · NMSCA
Nutrition Management Services Company
$0.00$0.00 (0.0%)
Nutrition Management Services Company’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
Loading market information…
OTC · BIOCQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Biocept, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Biocept, Inc.’s next earnings report is currently expected on Nov 24, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biocept, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biocept, Inc., established in 1997 and based in San Diego, California, was a molecular oncology diagnostics firm. Its primary business involved the development and commercialization of exclusive clinical laboratory assays within the United States. These advanced tests were engineered to detect elusive tumor cells and cell-free tumor DNA (ctDNA) from both blood and cerebrospinal fluid (CSF) samples. The insights provided by Biocept's cancer assays were instrumental for healthcare professionals, allowing them to pinpoint specific cancer-causing genetic mutations. This capability helped identify suitable cancer patients for targeted therapies, whether at the point of initial diagnosis, during disease progression, or for continuous monitoring to uncover resistance mechanisms. The company offered diagnostic solutions for a variety of solid tumor cancers, such as breast, non-small cell lung (NSCLC), gastric, colorectal, prostate, pancreaticobiliary, and ovarian cancers. Furthermore, Biocept extended specialized testing services for CSF tumor cells, ctDNA, and ctRNA to a diverse group of medical specialists, including medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, and pathologists. It also supplied clinical trial and research assistance to pharmaceutical and biopharmaceutical companies, along with clinical research organizations. Biocept participated in collaborations, notably with CLEARED4 to create a system for overseeing COVID-19 testing requirements and results for its clientele. Another partnership with Protean BioDiagnostics, Inc. aimed to evaluate the proficiency of its Target Selector molecular assay in ascertaining EGFR status in NSCLC patients. However, Biocept, Inc. voluntarily initiated liquidation proceedings by filing for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware on October 13, 2023.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Nutrition Management Services Company’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.00$0.00 (0.0%)
Verde Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Thoughtful Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
Nabriva Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Ormand Industries Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Plant-Based Investment Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Biostar Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
HTG Molecular Diagnostics, Inc.: Healthcare · Medical - Diagnostics & Research.
